International Open Medical Journal (IOMJ)

IOMJ Now Offers Free Image Polishing Service for Authors!

Why Utilize IOMJ’s Image Polishing? For all manuscripts that successfully pass the initial pre-check, our professional medical illustration team provides the following enhancements at no cost: Visual Optimization: We refine color schemes for maximum impact, ensuring they meet international standards for aesthetics and color-blind accessibility. Professional Standardization: We unify font types, line weights, and labeling styles across all figures, and resolve common resolution (DPI) issues. Logical Refinement: Our team assists in restructuring flowcharts and mechanistic diagrams to ensure the underlying scientific logic is rigorous and easy to follow. Zero Financial Burden: This service is fully funded by IOMJ. Our goal is to alleviate the technical and formatting pressures often faced by researchers during the late stages of publication. Service Scope This service covers all types of scientific visuals, including but not limited to: Clinical Imaging: Labeling and enhancement of OCT, fundus photography, MRI, etc. Experimental Data Visualization: Professional rendering of bar charts, scatter plots, and survival curves. Schematic Diagrams: Illustrations of biological pathways and molecular mechanisms. Surgical Procedures: Clear, step-by-step procedural flowcharts. How to Apply? There is no extra step required! Simply submit your manuscript through our standard portal. Once your paper moves into the peer-review or revision stage, our editorial team will proactively reach out to discuss potential visual optimizations for your work.

About the Journal

The International Open Medical Journal (IOMJ) (eISSN3069-0080) is the official publication of the International Medical Association. It was founded in August 2025, and operates as a double-blind, peer-reviewed, and diamond open access journal. This publication is aimed at a broad, interdisciplinary audience of academic and industrial researchers actively engaged in basic and applied laboratory practice related to biological and health sciences.

Submission to first decision: 24 Hours

Acceptance to online first: 3 Days

Submission to acceptance: 46 Days

APC: Free

Announcements

Inauguration ceremony of the IOMJ China Editorial Office

2025-12-14

Current Issue

Online First

Published: 2026-06-02

Original Research articles

Precision medicine of rare tumors: Uncovering the potential actionable targets through genomic profiling

Guomin Lin, Yue Hao, Qian Wang, Yuanzhi Lu, Tangfeng Lv, Youcai Zhu, Weiwei Pan, Shirong Zhang, Zhenying Guo, Xingxiang Pu, Zhengbo Song, Bin Lian, Chunwei Xu (Author)

244-254
- PDF
Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery

Man Zhang, Haiyan Sun, Sijia Xing, Yanyang Li, Gang Zhao , Huiya Wang, Ran Zuo, Shuang Li, Bin Wang, Zhuchen Yan, Jie Xu, Zhanyu Pan, Zhansheng Jiang (Author)

227-243
- XML
- PDF

Review articles

Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer

Danru Zheng, Chunwei Xu, Qian Wang, Wenxian Wang, Dong Wang, Fangcen Lan, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Wenfeng Fang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Yu Zhang, Anwen Liu, Wen Liu, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Gen Lin, Jingping Yuan, Zhansheng Jiang, Long Huang, Xingxiang Pu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Jin Zhou, Zhengfei Zhu, Xiaofeng Chen, Weiwei Pan, Xuewen Liu, Fei Pang, Kai Wang, Fan Wu, Bingwei Xu, Liping Wang, Youcai Zhu, Yanhong Shang, Jianfei Tu, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Huijing Feng, Lin Wang, Yingying Du, Yao Wang, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Zhaofeng Wang, Yue Hao, Jin Kang, Jiatao Zhang, Chao Zhang, Wenbin Gao, Zhen Wang, Bin Wan, Donglai Lv, Shengjie Yang, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhefeng Liu, Nong Yang, Lin Wu, Huijuan Wang, Xuelei Ma, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Yuan Li, Ke Wang, Yiping Zhang, Xixu Zhu, Yi Shen, Shenglin Ma, Yuanzhi Lu, Song Yong, Ziming Li, Zhengbo Song, Xiuyu Cai (Author)

103-168
- PDF
- XML
The gut-neuro-tumor signaling feedback driving dynamic remodeling of the tumor microenvironment

Yang Chen, Xuejuan Wang (Author)

191-226
- XML
- PDF

Correspondences

Efficacy and Safety of Small-Particle Cross-Linked Hyaluronic Acid Intradermal Injection for Improving Facial Skin Quality: A Retrospective Real-World Study

Chungyung Keung, Qinyang Li, Jianxun Mao, Shunnv Jin, Yuanyuan Lin, Qing Li (Author)

170-183
- PDF
- XML
Data Monitoring Committees in Chinese Clinical Trials: Institutional Empowerment and the New Landscape of Global Pharmaceutical Innovation

Yuexiang Huang (Author)

184-190
- XML
- PDF

Editorials

Beyond a Single KRAS Inhibitor: China-Originated Therapeutics and the Rise of Resistance-Directed Combinations

Yue Hao, Zhengbo Song (Author)

255-258
- PDF
- XML

View All Issues

International Open Medical Journal (IOMJ)

About the Journal

Announcements

Inauguration ceremony of the IOMJ China Editorial Office

Current Issue

Original Research articles

Precision medicine of rare tumors: Uncovering the potential actionable targets through genomic profiling

Oral etoposide plus anlotinib and subcutaneous envafolimab as a platinum‑free, non‑intravenous first‑line regimen for elderly extensive‑stage small cell lung cancer: a phase II trial with biomarker discovery

Review articles

Expert consensus on immune checkpoint inhibitors for non-small cell lung cancer

The gut-neuro-tumor signaling feedback driving dynamic remodeling of the tumor microenvironment

Correspondences

Efficacy and Safety of Small-Particle Cross-Linked Hyaluronic Acid Intradermal Injection for Improving Facial Skin Quality: A Retrospective Real-World Study

Data Monitoring Committees in Chinese Clinical Trials: Institutional Empowerment and the New Landscape of Global Pharmaceutical Innovation

Editorials

Beyond a Single KRAS Inhibitor: China-Originated Therapeutics and the Rise of Resistance-Directed Combinations

Make a Submission

Language

Index

Membership

Publishing Information